stockrow
Friday 6 November 2026
Export GLAS’s income statement to Excel — free account
Glass House Brands Inc.
GLAS Healthcare Drug Manufacturers Specialty & Generic
Glass House Brands Inc.’s revenue for fiscal 2025 (year ended December 2025) was $182.0 million, down 9.41% from fiscal 2024.
- Revenue
- −1.24%
- EPS
- −320.0%
- Free cash flow
- −123.4%
- Total debt
- −17.2%
Quarter to June 2026, against a year earlier
2.28
0.30
−11.63%
Follow GLAS
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+7 more quarters Free account |
P/S ratio |
6.52 | 4.00 | 3.98 | 3.37 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
6,446.33 | (60.48) | (195.93) | (122.60) | |
P/B ratio |
15.89 | 8.37 | 8.83 | 6.95 | |
Price to Tangible BV |
16.09 | 9.70 | 8.92 | 8.01 | |
EV/Sales |
6.73 | 4.25 | 4.30 | 3.61 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 49.28 | |
EV/Operating CF |
(58.57) | (271.76) | 68.29 | 28.46 | |
EV/FCF |
(32.37) | (28.41) | (50.40) | (166.08) | |
Quick Ratio |
0.55 | 0.79 | 0.46 | 1.03 | |
Current Ratio |
1.33 | 1.85 | 1.78 | 2.24 | |
Net Debt/EBITDA |
46.53 | (4.29) | (6.83) | (5.93) | |
Debt/Assets |
17.78% | 21.12% | 21.69% | 21.91% | |
Debt/Equity |
0.77 | 0.81 | 0.84 | 0.79 | |
Asset Turnover |
0.55 | 0.56 | 0.58 | 0.59 | |
Operating CF/Net income |
(0.02) | 0.59 | 0.20 | 0.33 | |
Capex/Depreciation |
(0.56) | (0.88) | (0.54) | (2.16) | |
Interest Coverage |
(4.77) | (11.08) | (11.40) | (6.26) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
29.23% | 43.14% | 46.76% | 43.25% | |
Intangible Assets out of Total Assets |
0.00 | 0.04 | 0.00 | 0.04 | |
Share Based Compensation of Revenue |
8.96% | 11.16% | 8.36% | 10.61% | |
Graham Net Nets |
(0.15) | (0.23) | (0.23) | (0.25) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(5.85%) | (7.35%) | (6.21%) | (2.93%) | |
Free Cash Flow Yield |
(3.19%) | (3.74%) | (2.14%) | (0.64%) | |
Revenue per Share |
0.53 | 0.47 | 0.62 | 0.47 | |
Operating CF per Share |
0.00 | (0.13) | (0.05) | (0.06) | |
Capex per Share |
(0.02) | (0.04) | (0.03) | (0.10) | |
Free Cash Flow per Share |
(0.02) | (0.18) | (0.07) | (0.17) | |
Cash per Share |
0.21 | 0.28 | 0.15 | 0.32 | |
Shareholders Equity per Share |
0.82 | 0.98 | 1.00 | 1.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.82 | 0.98 | 1.00 | 1.08 | |
Free Cash Flow |
(1.93) | (15.30) | (5.88) | (13.69) | |
Working Capital |
17.85 | 34.15 | 29.79 | 41.11 | |
Capital Expenditures |
(2.11) | (3.55) | (2.18) | (8.63) | |
Net Current Asset Value |
(169.53) | (166.05) | (168.71) | (156.22) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.09 | 0.04 | 0.22 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.80 | 7.92 | 6.17 | 5.99 | |
Average Payables |
37.79 | 34.39 | 29.69 | 27.85 | |
Average Inventory |
26.85 | 23.61 | 19.28 | 14.11 | |
Average Assets |
323.97 | 318.47 | 314.53 | 311.80 | |
Average Common Equity |
86.58 | 85.25 | 79.90 | 78.17 |
Columns are period end dates · fundamentals updated 2 Nov 2026